Purpose of Review
Over the last two decades the pathogenic basis for the most common heritable cardiovascular disease, hypertrophic cardiomyopathy (HCM), has been investigated extensively. Affecting approximately 1 in 500 individuals, HCM is the most common cause of sudden death in young athletes. In recent years, genomic medicine has been moving from the bench to the bedside throughout all medical disciplines including cardiology. Now, genomic medicine has entered clinical practice as it pertains to the evaluation and management of patients with HCM. The continuous research and discoveries of new HCM-susceptibility genes, the growing amount of data from genotype-phenotype correlation studies, and the introduction of commercially available genetic tests for HCM make it essential that the modern-day cardiologist understand the diagnostic, prognostic, and therapeutic implications of HCM genetic testing.
Affecting 1 in 500 people, hypertrophic cardiomyopathy (HCM) is a disease marked by phenotypic and genotypic heterogeneity and is the most prevalent, heritable cardiovascular disease. HCM is the most common cause of sudden cardiac death in young athletes [1] . HCM can manifest negligible to extreme hypertrophy, minimal to extensive fibrosis and myocyte disarray on microscopy, absent to severe left ventricular outflow tract (LVOT) obstruction, and distinct septal morphologies such as reverse curve-, sigmoidal-, and apical-HCM. The clinical course varies extremely as well, ranging from an asymptomatic lifelong course to dyspnea/angina refractory to pharmacotherapy to sudden death as the sentinel event. Fully described for the first time by Teare in 1958, HCM was regarded as 'asymmetrical hypertrophy of the heart in young adults' [2] . It has since been referred to by an array of names -idiopathic hypertrophic subaortic stenosis [3] , muscular subaortic stenosis [4] and hypertrophic obstructive cardiomyopathy [5] -reflecting its clinical heterogeneity and its relatively uncommon occurrence in daily cardiologic practice.
Diagnostic Implications of HCM Genetic Testing

Identification of HCM-Susceptibility Genes
Nearly 20 years ago, the first chromosome locus for familial HCM and subsequently mutations involving the MYH7-encoded -myosin heavy chain were elucidated as the pathogenic basis for HCM [6, 7] . Since then several hundreds of mutations scattered among at least 27 putative HCM-susceptibility genes encoding various sarcomeric, calcium-handling and mitochondrial proteins have been identified (Table 1 , 2). The most common genetically-mediated form of HCM is myofilament (sarcomeric)-HCM with hundreds of disease-associated mutations in 9 genes encoding proteins (myofilaments) critical to the cardiac sarcomere. This includes -myosin heavy chain (MYH7) [7] , regulatory -(MYL2) and essential myosin light chains (MYL3) [8] , myosin binding protein C (MYBPC3) [9] , cardiac troponin T (TNNT2), -tropomyosin (TPM1) [10] , cardiac troponin I (TNNI3) [11] , cardiac troponin C (TNNC1) [12] and actin (ACTC) [13, 14] . Complete screening through a large cohort of patients has not been performed, yet targeted screening of giant sarcomeric TTN-encoded titin, which extends throughout half of the sarcomere, has thus far revealed only 1 mutation [15] . Expanding the scope of proteins involved in the pathogenesis of HCM, the spectrum of HCM-associated genes has moved outside the myofilaments of the sarcomere to encompass additional subgroups that could be classified as 'Z-disc-HCM' and 'calcium-handling HCM' (Table 1) . Due to its close proximity to the contractile apparatus of the myofilament, its specific structure-function relationship with regards to cyto-architecture, as well as its role in the stretch-sensor mechanism of the sarcomere, attention subsequently focused on the cardiac Z-disc. This focus has been fueled by the fact that HCM and DCM are partially allelic disorders, in which mutations in the same genes -especially the Z-disc -can be responsible for both cardiomyopathic phenotypes [16, 17, 18, 19, 20, 21, 22, 23, 24] . The first Z-disc mutations associated with HCM were described in muscle LIM protein encoded by CSRP3 [21] and telethonin encoded by TCAP [23] . differentially expressed genes between transgenic and non-transgenic mice were detected, of which 266 were differentially regulated between the 2 different mutant hearts showing most significant changes in genes belonging to the 'secreted/extracellular matrix' (up-regulation) and 'metabolic enzymes' (downregulation) [35] .
Another emerging field is that of microRNA's (miR's) and their role in cardiac development and (hypertrophic) heart disease. These fundamental cellular regulators were first described by Lee et al in 1993 [36] and consist of approximately 22 noncoding RNA molecules that silence genes through posttranscriptional regulation.
MicroRNA's play an important role in cardiac development as well as in orchestrating organogenesis and early embryonic patterning processes [37, 38] . Furthermore, these non-coding RNA molecules seem to play an important role in cardiac remodeling and the development of hypertrophy as initially reported by Van Rooij et al in 2006 (42) .
Utilizing 2 mouse models of pathological hypertrophy -transverse aortic constriction (TAC) and calcineurin transgenic mice, 6 miR's were up-regulated, which in vitro, were sufficient to induce hypertrophic growth of cardiomyocytes [39] . Furthermore, a transgenic mouse model over-expressing one of these miR's (miR-195) showed that a single miRNA could induce pathological hypertrophy and heart failure [39] . Over the last year, multiple studies have been published with miRNA expression profiles in different settings, in vivo and in vitro, of cardiac hypertrophy [37, 39, 40, 41, 42, 43] .
Lastly, PMAGE (polony multiplex analysis of gene expression) is a technique
that detects messenger RNAs (mRNAs) as rare as one transcript per three cells [44] .
Using this new technique, early transcriptional changes preceding pathological manifestations were identified in mice with HCM-causing mutations, including lowabundance mRNA encoding signaling molecules and transcription factors that participate in the disease pathogenesis [44] .
The development and implementation of these new techniques as well as their applications in research and clinical models of cardiac hypertrophy and HCM will over the years teach us more about the pathophysiology of normal and pathologic hypertrophy as well as HCM. This in turn might lead to discovery of novel disease causing genes, involved pathways and possible novel therapeutic targets.
HCM Genetic Testing in Clinical Practice
Recently, HCM genetic testing has matured from its two-decade long residence in research laboratories into the realm of clinically available, diagnostic testing for physicians evaluating and treating patients with this disease [(Harvard Partners, Correlagen, PGxHealth, and GeneDx. These companies now offer testing for the 8 most common myofilament associated genes; additional genes offered by some are the genes involved in the glycogen storage diseases or the recently discovered HCMassociated gene troponin C encoded by TNNC1. The HCM-susceptibility genes available for commercial genetic testing are highlighted in bold in Table 1 and 2.
Although some of the new HCM-susceptibility genes may surpass the prevalence of mutations found in some of the myofilament proteins, MYBPC3 and MYH7 remain by far the most common HCM-associated genes, with an estimated prevalence of 15 to 25% for both genes. Among the 9 HCM-associated, myofilament encoding genes, the prevalence of myofilament-HCM has ranged from 35 to 65% in several different, international cohorts of unrelated patients who met the clinically accepted definition of HCM [45, 46] .
Echo-guided genetic testing
While several phenotype-genotype relationships have emerged to enrich the yield of genetic testing, most of these patient profiles have not been particularly clinically informative. Recently, the possibility of echo-guided genetic testing has been explored [47] . Noting a predominance of sigmoidal-HCM among the elderly, Lever et al suggested over 2 decades ago that there was a strong age-dependence with the various septal morphologies of HCM, where septal contour was classified as reverse curve-, sigmoidal-, apical-, and neutral contour-HCM (Figure 1)[48] . In the early 1990s, Solomon et al observed that patients with mutations in the beta myosin heavy chain (MYH7-HCM) generally had reversed curvature septal contours (reverse curve-HCM)
[49]. Subsequently, a large genotype-phenotype analysis correlating the septal morphology with the underlying genotype was conducted. After extensive analysis of the echocardiograms of nearly 400 unrelated patients, sigmoidal HCM (47% of cohort) and reverse curve-HCM (35% of cohort) represented the two most prevalent anatomical subtypes of HCM (Figure 1) . In this study, the yield of genetic testing for myofilament-HCM (8 genes) was 80% in reverse curve-HCM but only 10% in patients with sigmoidal-HCM and septal contour was the strongest predictor of a positive HCM genetic test, regardless of age (odds ratio 21, p <0.0001) [47] . These observations may facilitate echo-guided genetic testing by enabling informed genetic counseling about the pre-test probability of a positive genetic test based upon the patient's expressed anatomical phenotype (Figure 2 ).
Role of HCM genetic testing for both index cases and relatives
Although there may be some prognostic relevance presently and therapeutic relevance futuristically to the HCM genetic test in the index case who already clinically manifests the disease, the principal role for index case genetic testing is diagnostic. It can however, as we will show later on, be of significant importance to the approach and screening of relatives. Noted is the a priori probability for a positive genetic test result based on the echocardiographic scored septal contour, as well as the steps to follow if a patient chooses not to pursue genetic testing.
As it stands now, genetic testing of the index case for the index case has the potential of providing the diagnostic gold standard for his/her offspring, siblings, and Aside from the role of genetic testing described above, there is still concern among patients and practitioners on social and economic aspects of knowing ones genetic make-up. 
Prognostic Implications of HCM Genetic Testing
From the early-beginnings of the genomic-era and since the description of the first HCM-causing mutation, investigators have attempted to correlate genotypes to particular clinical phenotypic expressions. Stemming from earlier pedigree studies, specific missense mutations were associated with a markedly unfavorable prognosis whereas others had an uneventful natural history. These observations resulted in specific mutations being designated as either "malignant" mutations or "benign"
mutations [61, 62, 63, 64, 65, 66, 67, 68] . The first study of its kind was published by
Watkins et al. in 1992 in which they described mutations in MYH7 found in 12 out of 25 families with HCM [61] . They concluded that the MYH7-R403C mutation was associated with a significantly shorter life expectancy, and could therefore be considered a 'malignant' mutation. In contrast, a non-charge change mutation (V606M)
was associated with nearly normal survival and therefore was considered 'benign' [61] . mild phenotypic expression that are present in at least 30% of their cases [72] .
Similarly, certain genotype-phenotype correlations were attributed to TNNT2 (troponin T)-HCM. Far less common than MYBPC-HCM or MYH7-HCM, TNNT2-HCM (affecting < 5% of patients) was associated with less severe left ventricular wall thickness, but a higher incidence of premature sudden cardiac death [64, 73, 74] . Overall, these TNNT2-HCM patients who suddenly died had less hypertrophy and less fibrosis, but more myocyte disarray, which may have provided the substrate for malignant arrhythmias [74] .
Overall, these observations have been gleaned from small cohorts involving larger families with penetrant disease expression whereas genotype-phenotype studies involving large cohorts of unrelated patients have indicated that great caution must be exercised with assigning particular prognostic significance to any particular mutation [75, 76, 77] . In one such cohort, only 2% hosted one of those formally annotated 'benign' mutations and moreover, these particular hosts displayed a severe clinical phenotype with all 5 patients requiring surgical myectomy, 3 of the 5 having a family history of sudden cardiac death, and 1 adolescent requiring an orthotopic heart transplant [77] . In contrast, 3 patients hosting a so-called 'malignant' mutation displayed a heretofore mild phenotype [75] . Furthermore, these studies have demonstrated that the two most common forms of genetically mediated HCM -MYH7-HCM and MYBPC3-HCM -are phenotypically indistinguishable [78] .
More recently, in one of the first studies of its kind for HCM, a longitudinal study in a large cohort of unrelated Italian patients with HCM have shown an increased risk of cardiovascular death, non-fatal stroke or progression to New York Heart Association functional class III/IV among patients with a positive HCM genetic test involving any of the myofilament genes compared to those patients with a negative genetic test (25% vs. 7%, respectively; p = 0.002) ( Figure 3A) ; multivariate analysis showed myofilament positive HCM (i.e. a positive genetic test) to be the strongest predictor of an adverse outcome (hazard ratio 4.27 (CI 1.43 -12.48), p = 0.008) [79] . Furthermore, patients with myofilament genotype-positive-HCM had greater probability of developing severe LV systolic dysfunction (p = 0.021; Figure 3B ) and restrictive LV filling (p = 0.018; Figure 3C ).
Lastly, it has been observed that patients with multiple mutations (i.e.
compound or double heterozygotes), detected in about 3-5% of genotype positive patients, have a more severe phenotype and increased incidence of sudden death [78, 80, 81] , suggesting a gene-dosage effect might contribute to disease severity.
Interestingly, in the majority of cases of compound heterozygosity, one of the mutations usually involves MYBPC3 [78] . In their longitudinal study, Olivotto et al.
observed a similar trend showing that patients with double mutations (of which 1 was usually MYBPC3) had greater disease severity than myofilament negative patients or patients with a single MYBPC3 -, thick filament -or thin filament mutation combined (p < 0.05; Figure 3D ). In summary, although clinical prognostication must be rendered with great caution for specific gene domains or specific genetic mutations, a positive HCM genetic test in general portends a greater likelihood for disease progression, particularly as it pertains to systolic and diastolic dysfunction and propensity to develop symptoms. As such, clinical genetic testing may thereby aid in the prognostication of a patient's disease outcome.
Interpretation of rare variants and phenocopies
One group of patients that pose an intriguing challenge for clinicians is that of patients with seemingly unexplained LVH that mimics the HCM-phenotype. These diseases are usually referred to as phenocopies and the most important ones are listed in Table 2 [92] .
Role of modifiers in HCM
The role of modifiers of the HCM phenotype, either by the presence of common polymorphisms or founder-mutations, has become the subject of recent investigations.
The most important subgroup of polymorphisms, studied to date, involve the major components of the renin-angiotensin-aldosterone system (RAAS). Polymorphisms in the RAAS-pathway [angiotensionogen-I converting enzyme (ACE), angiotensin receptor 1 (AGTR1), chymase 1 (CMA), angiotensin I (AGT) and cytochrome P450, polypeptide 2 (CYP11B2)): DD-ACE, CC-AGTR1, AA-CMA, T174M-and M235T-AGT, and CC-CYP11B2] appear to influence the HCM phenotype, in particular the severity of LVH [93, 94] . Among patients with the DD-ACE genotype, there was greater LVH than among those with an ID or II genotype [95] . Furthermore, a combined 'pro-LVH' profile of five RAAS-genes was associated with higher degree of LVH in one particular, founder MYPBC3-HCM pedigree [93] and in a large cohort of myofilament positive patients [94] .
In 2008, sex hormone polymorphisms were shown to modify the HCM phenotype (104) . Fewer CAG repeats in AR-encoded androgen receptor were associated with thicker myocardial walls in male subjects (p = 0.008) and male carriers of the A-allele in the promoter of ESR1-encoded estrogen receptor 1 (SNP rs6915267) exhibited a 11% decrease in LV wall thickness (p = 0.047) compared to GGhomozygote male subjects [96] . HCM modifier polymorphisms like these could contribute to the clinical differences observed between men and women with HCM [97, 98] . The release of the complete human genome sequence and the enormity of variation in individuals show a growing role for modifier genes and the search for effect by genome-wide studies. In 2007, Daw et al. performed the first study of this kind for HCM and they identified multiple loci with suggestive linkage. Effect sizes on left ventricular mass on this cohort of 100 patients ranged range from ~8g shift from one locus for the common allele to 90g shift for another locus' uncommon allele [99] . improved diastolic function and prevented diastolic heart failure and sudden cardiac death compared to untreated mice [101] .
Therapeutic Implications of HCM Genetic Testing
As previously discussed, RAAS polymorphisms modify the phenotype of HCM, particularly MYBPC3-HCM [93, 94] and there is now growing evidence that ACEinhibitors especially combined with low doses of aldosterone receptor blockers may attenuate the progression of hypertrophy and fibrosis [102, 103, 104, 105, 106] . In early mouse-models of transgenic cardiac troponin T (cTnT-Q92) that exhibit myocyte disarray and fibrosis, a randomized, blinded trial comparing losartan (an angiotensin-II blocker) or placebo demonstrated that losartan significantly reversed fibrosis and expression of collagen 1 (I) and TGF -1 in the transgenic mice [107] . In a similar study involving the same transgenic mice, losartan produced a 50% reduction in myocyte disarray compared to mice treated with placebo as well as complete normalization of the collagen volume fraction [108] .
Lastly, another group of drugs, statins, may favorably modify the phenotype of hypertrophic cardiomyopathy. A study involving 24 transgenic mice harboring the MYH7 R403Q-mutation showed a regression of hypertrophy and fibrosis, improved cardiac function and reduced ERK1/2 activity after treatment with simvastatin compared to 12 non-transgenic mice [109] . Similar results were observed in transgenic rabbits with this mutation who were treated with atorvastatin [110] . However, a small, randomized control pilot study failed to show an effect on humans with HCM [111] .
Therefore, one can envision that, with increasing knowledge of the patient's pathogenic substrate and polymorphism profile, specific therapies may someday 
Conclusions
Genomic medicine, as it pertains to HCM, has moved from the bench to the bedside, but caution is needed to interpret and manage the genetic portfolio of a patient.
Although some prognostic forecasts may be gleaned from the HCM genetic test, therapeutic decisions regarding use of a defibrillator should not be dictated by the genetic test result. Instead, knowledge of the genetic background in subjects with HCM has significant diagnostic implications and echocardiography may help guide genetic testing by providing anticipatory guidance and a pre-test probability of a positive genetic test result. Clearly, knowledge of disease-causing mutations in an index case enables rapid genetic testing and diagnosis of potentially at-risk relatives thereby providing improved and informed follow-up and treatment decisions for such family members. The information gained in these subjects can define risk status and, in those subjects with negative genetic screening, less close follow-up and testing over time and psychological freedom.
Increasingly, clinical care in HCM and other genetic-based disorders includes the wise use and wiser interpretation of genetic tests. Therefore, understanding the genetic underpinnings of disease and the risk placed on these subjects will be imperative for all patients and their families. The 21st century clinician must be cognizant of the state-of-the-art of translational genetics in order to best care for their patients and families, as well as to help to define new clinical guidelines over the next decade.
